LAM-002A

DRUG3 trials

Sponsors

OrphAI Therapeutics

Conditions

ALSAmyotrophic Lateral SclerosisFrontotemporal DementiaLymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic

Phase 1

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

CompletedNCT02594384

OrphAI TherapeuticsLymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic

Start: 2015-10-31End: 2023-03-30Updated: 2024-08-22

Phase 2

Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis

CompletedNCT05163886

OrphAI TherapeuticsALS, Amyotrophic Lateral Sclerosis

Start: 2021-12-23End: 2025-05-31Updated: 2025-06-22

Unknown Phase

An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)

OrphAI TherapeuticsFrontotemporal Dementia

Updated: 2022-08-02

Related Papers

Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial

Brain2024-04-1219 citations

Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers.

Journal of Clinical Oncology2020-05-209 citations